Compare
COMPASS Pathways plc vs Puma Biotechnology, Inc. vs Siga Technologies Inc vs Abeona Therapeutics Inc.
| Latest fiscal year | COMPASS Pathways plc CMPS | Puma Biotechnology, Inc. PBYI | Siga Technologies Inc SIGA | Abeona Therapeutics Inc. ABEORevenue covers only part of its income (partial revenue) |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $228.37M | $94.57M | n/a |
| Revenue growth (YoY) | n/a | -0.9% | -31.8% | n/a |
| Gross margin | n/a | 74.5% (computed) | 68.6% (computed) | n/a |
| Operating margin | n/a | 16.3% | 25.1% | n/a |
| Net margin | n/a | 13.6% | 24.6% | n/a |
| Net income | -$287.86M | $31.11M | $23.28M | $71.18M |
| EPS (Diluted) | -$3.08 | $0.61 | $0.32 | $1.01 |
| Operating cash flow | -$157.24M | $41.80M | $43.47M | -$76.33M |
| Free cash flow | n/a | $41.73M | n/a | -$84.30M |
| Cash & equivalents | $149.61M | $29.64M | $154.97M | $78.44M |
| Total assets | $210.35M | $216.30M | $219.47M | $219.57M |
| Total liabilities | $263.20M | $85.96M | $20.65M | $60.35M |
| Shareholders' equity | -$52.85M | $130.34M | $198.82M | $159.22M |
| Return on year-end equity | n/a | 23.9% | 11.7% | 44.7% |
| Shares outstanding | 96.09M | 50.41M | 71.61M | 55.04M |
Revenue, most recent five fiscal years
| Fiscal year | COMPASS Pathways plc | Puma Biotechnology, Inc. | Siga Technologies Inc | Abeona Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | $228.37M Ended 2025-12-31 | $94.57M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $230.47M Ended 2024-12-31 | $138.72M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $235.64M Ended 2023-12-31 | $139.92M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $228.03M Ended 2022-12-31 | $110.78M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $253.16M Ended 2021-12-31 | $133.67M Ended 2021-12-31 | n/a |